X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8479) 8479
Book Review (1322) 1322
Publication (615) 615
Newsletter (189) 189
Book Chapter (24) 24
Dissertation (19) 19
Newspaper Article (15) 15
Conference Proceeding (14) 14
Book / eBook (2) 2
Magazine Article (2) 2
Reference (2) 2
Transcript (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7110) 7110
paclitaxel (5923) 5923
humans (5762) 5762
female (3509) 3509
oncology (3252) 3252
cancer (2779) 2779
animals (2770) 2770
pharmacology & pharmacy (2709) 2709
chemotherapy (2561) 2561
paclitaxel - administration & dosage (2515) 2515
male (2072) 2072
middle aged (1846) 1846
aged (1700) 1700
paclitaxel - pharmacokinetics (1654) 1654
pharmacokinetics (1648) 1648
mice (1542) 1542
adult (1508) 1508
nanoparticles (1459) 1459
cell line, tumor (1400) 1400
drug delivery systems (1363) 1363
antineoplastic combined chemotherapy protocols - therapeutic use (1239) 1239
drugs (1136) 1136
paclitaxel - pharmacology (1050) 1050
treatment outcome (1039) 1039
taxol (1021) 1021
antineoplastic agents, phytogenic - administration & dosage (996) 996
docetaxel (983) 983
breast neoplasms - drug therapy (940) 940
paclitaxel - therapeutic use (939) 939
tumors (916) 916
breast cancer (904) 904
care and treatment (902) 902
in-vitro (900) 900
neoplasms - drug therapy (896) 896
research (883) 883
antineoplastic agents, phytogenic - pharmacokinetics (881) 881
analysis (869) 869
antineoplastic agents (821) 821
doxorubicin (818) 818
therapy (798) 798
dose-response relationship, drug (795) 795
antimitotic agents (784) 784
cisplatin (783) 783
drug-delivery (776) 776
antineoplastic agents - administration & dosage (763) 763
paclitaxel - adverse effects (759) 759
vehicles (729) 729
paclitaxel - chemistry (728) 728
medicine & public health (705) 705
drug therapy (703) 703
lung neoplasms - drug therapy (689) 689
antineoplastic combined chemotherapy protocols - adverse effects (681) 681
chemistry, multidisciplinary (674) 674
antineoplastic agents - therapeutic use (663) 663
rats (657) 657
carboplatin (643) 643
micelles (639) 639
breast-cancer (638) 638
nanoparticles - chemistry (624) 624
drug administration schedule (621) 621
trial (618) 618
antineoplastic agents - pharmacology (612) 612
ovarian neoplasms - drug therapy (612) 612
drug carriers - chemistry (597) 597
antineoplastic agents - pharmacokinetics (594) 594
toxicity (587) 587
ovarian cancer (583) 583
cell survival - drug effects (572) 572
pharmacology/toxicology (571) 571
health aspects (564) 564
antineoplastic agents, phytogenic - therapeutic use (548) 548
mice, nude (547) 547
tissue distribution (540) 540
delivery (535) 535
apoptosis (529) 529
combination (529) 529
particle size (529) 529
drug delivery (523) 523
p-glycoprotein (522) 522
breast neoplasms - pathology (521) 521
metastasis (512) 512
carcinoma, non-small-cell lung - drug therapy (508) 508
carcinoma (503) 503
cell lung-cancer (497) 497
article (494) 494
nanoscience & nanotechnology (493) 493
antineoplastic combined chemotherapy protocols - administration & dosage (489) 489
paclitaxel - analogs & derivatives (487) 487
cytotoxicity (480) 480
antineoplastic agents, phytogenic - pharmacology (478) 478
cancer therapies (474) 474
in-vivo (463) 463
mice, inbred balb c (463) 463
cells (461) 461
carboplatin - administration & dosage (448) 448
ovarian-cancer (435) 435
solid tumors (433) 433
clinical trials (432) 432
polyethylene glycols - chemistry (429) 429
xenograft model antitumor assays (429) 429
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8619) 8619
Japanese (34) 34
Chinese (21) 21
French (19) 19
Korean (12) 12
German (6) 6
Spanish (5) 5
Polish (3) 3
Czech (2) 2
Hungarian (2) 2
Portuguese (2) 2
Dutch (1) 1
Italian (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1512 - 1522
Antibody–drug conjugates have emerged as a powerful strategy in cancer therapy and combine the ability of monoclonal antibodies to specifically target tumour... 
HETEROGENEITY | EMTANSINE | THERAPY | ONCOLOGY | CANCER AMERICAN SOCIETY | CLINICAL-PRACTICE GUIDELINE | GENE AMPLIFICATION | JUNCTION CANCER | HER2 STATUS | OPEN-LABEL | PLUS PACLITAXEL | Breast Neoplasms - surgery | Prognosis | Receptor, ErbB-2 - genetics | Trastuzumab - pharmacokinetics | Humans | Middle Aged | Mastectomy - methods | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Patient Safety | Esophageal Neoplasms - mortality | Immunoconjugates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Receptor, ErbB-2 - drug effects | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Trastuzumab - therapeutic use | Drug Administration Schedule | Japan | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - genetics | Esophageal Neoplasms - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Antimitotic agents | Care and treatment | Safety and security measures | Monoclonal antibodies | Antineoplastic agents | Biopharmaceutics | Tumors | Enzymes | Medical research | Analysis | Medicine, Experimental | Health aspects | Index Medicus
Journal Article
Journal Article
Biomaterials, ISSN 0142-9612, 2007, Volume 29, Issue 9, pp. 1233 - 1241
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2014, Volume 74, Issue 3, pp. 457 - 463
Journal Article
Science, ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Index Medicus | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2014, Volume 9, Issue 1, pp. e82331 - e82331
Brain cancer is a devastating disease affecting many people worldwide. Effective treatment with chemotherapeutics is limited due to the presence of the... 
MALIGNANT GLIOMA | CELLS | TRANSPORT | MULTIDISCIPLINARY SCIENCES | BARRIER | METASTASES | ADRIAMYCIN | BIODISTRIBUTION | MODEL | CHEMOTHERAPY | PACLITAXEL | Doxorubicin - blood | Glutathione - pharmacokinetics | Doxorubicin - therapeutic use | Capillaries - pathology | Humans | Brain Neoplasms - pathology | Body Weight - drug effects | Polyethylene Glycols - therapeutic use | Drug Delivery Systems | Brain - blood supply | Glutathione - pharmacology | Time Factors | Doxorubicin - analogs & derivatives | Female | Polyethylene Glycols - pharmacology | Glutathione - therapeutic use | Tissue Distribution - drug effects | Glutathione - analogs & derivatives | Endothelial Cells - metabolism | Polyethylene Glycols - pharmacokinetics | Treatment Outcome | Brain Neoplasms - drug therapy | Doxorubicin - pharmacokinetics | Brain - drug effects | Animals | Mice, Nude | Glioblastoma - pathology | Survival Analysis | Brain - pathology | Cell Proliferation - drug effects | Mice | Brain Neoplasms - ultrastructure | Endothelial Cells - pathology | Glioblastoma - drug therapy | Doxorubicin - pharmacology | Glutathione - blood | Drugs | Plasma physics | Drug delivery systems | Anthracyclines | Thiols | Gliomas | Brain tumors | Drug therapy | Cancer | Vehicles | Nuclear medicine | Bioluminescence | Neurosciences | Brain cancer | Glioblastoma | Drug delivery | Metastasis | Cancer therapies | Doxorubicin | Antioxidants | Blood-brain barrier | Inhibition | Xenobiotics | Glutathione | Medical treatment | Pharmacology | Breast cancer | Disease control | Endothelial cells | Studies | Chemotherapy | Brain research | Diffusion barriers | Medical prognosis | Pharmacokinetics | Tumors | Index Medicus
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 09/2019, Volume 174, pp. 728 - 733
Xiao-Ai-Ping injection (XAP) has been shown to be clinically effective in treatment of gastric carcinoma, liver cancer and lung cancer, when it was combined... 
LC-MS/MS | Xiao-Ai-Ping injection | 3’-p-hydroxypaclitaxel | Pharmacokinetics | Paclitaxel | Antimitotic agents | Liver cancer | Drug resistance in microorganisms | Lung cancer | Cytochrome P-450 | Liquid chromatography | Antineoplastic agents | Mass spectrometry | Methods | Index Medicus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 10/2012, Volume 163, Issue 1, pp. 93 - 99
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2002, Volume 94, Issue 24, pp. 1883 - 1888
The prescribed dose of anticancer agents is most commonly calculated using body surface area as the only independent variable, and it has been shown that this... 
TOPOISOMERASE-I INHIBITOR | INTRAVENOUS CISPLATIN | DOSE-ESCALATION | ADVANCED SOLID TUMORS | ONCOLOGY | ORAL TOPOTECAN | MATRIX-METALLOPROTEINASE INHIBITOR | SCHEDULE | CLINICAL PHARMACOKINETICS | PHASE-I | CREMOPHOR EL | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Drugs, Investigational - pharmacokinetics | Cytosine - administration & dosage | Male | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - administration & dosage | Uracil - administration & dosage | Dacarbazine - analogs & derivatives | Adult | Dacarbazine - pharmacokinetics | Dioxolanes - pharmacokinetics | Female | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Body Surface Area | Paclitaxel - administration & dosage | Dacarbazine - administration & dosage | Cytosine - pharmacokinetics | Drug Administration Schedule | Docosahexaenoic Acids - administration & dosage | Docosahexaenoic Acids - pharmacokinetics | Drugs, Investigational - administration & dosage | Dioxolanes - administration & dosage | Infusions, Intravenous | Temozolomide | Fluorouracil - pharmacokinetics | Uracil - pharmacokinetics | Clinical Trials, Phase I as Topic | Uracil - analogs & derivatives | Antimitotic agents | Drug metabolism | Dosage and administration | Testolactone | Antineoplastic agents | Analysis | Studies | Medical research | Adults | History | Cancer | Index Medicus
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2014, Volume 54, Issue 10, pp. 1097 - 1107
Journal Article